SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY

被引：0
|
作者：
Forsythe, A. [1 ]
Arondekar, B. [2 ]
Tremblay, G. [1 ]
Chan, G. [2 ]
Su, Y. [3 ]
机构：
[1] Purple Squirrel Econ, New York, NY USA
[2] Pfizer Inc, Collegeville, PA USA
[3] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.103
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN21
引用
收藏
页码：A415 / A415
页数：1
相关论文
共 50 条
  • [1] SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISON OF GLASDEGIB PLUS LOW DOSE ARA-C VERSUS A HYPOMETHYLATING AGENT FOR ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
    Forsythe, A.
    Arondekar, B.
    Tremblay, G.
    Chan, G.
    Su, Y.
    HAEMATOLOGICA, 2017, 102 : 380 - 380
  • [2] Covariate Adjusted Indirect Treatment Comparison (ITC) of Glasdegib Plus Low Dose Ara-C Versus a Hypomethylating Agent for Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
    Tremblay, Gabriel
    Arondekar, Bhakti
    Chan, Geoffrey
    Shor, Anastasiya
    Forsythe, Anna
    Yun, Su
    BLOOD, 2017, 130
  • [3] Systematic literature review and indirect treatment comparisons (ITC) of glasdegib (GLAS) plus low dose ara-c (LDAC) versus a hypomethylating agent (HMA) for previously untreated acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy (NIC).
    Forsythe, Anna
    Arondekar, Bhakti
    Tremblay, Gabriel
    Chan, Geoffrey
    Su, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Down Syndrome with Acute Myeloid Leukemia in an Adolescent Male Successfully Treated with Low Dose Ara-C in Combination with Hypomethylating Agent
    Ramakrishnan, Ramya
    Munir, Faryal
    Quesada, Andres E.
    Tewari, Sanjit Om
    Cuglievan, Branko
    BLOOD, 2023, 142
  • [5] Clinical Responses of Glasdegibplus Low Dose Ara-C, Azacitidine, and Decitabine Among Acute Myeloid Leukemia (AML) Patients Ineligible to Receive Intensive Chemotherapy: Comparative Effectiveness Using Indirect Treatment Comparison (ITC) Methods
    Westley, Tracy
    Forsythe, Anna
    Bell, Timothy J.
    Cappelleri, Joseph C.
    Tremblay, Gabriel
    Chan, Geoffrey
    BLOOD, 2018, 132
  • [6] Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia
    Dennis, Mike
    Russell, Nigel
    Hills, Robert K.
    Hemmaway, Claire
    Panoskaltsis, Nicki
    McMullin, Mary-Frances
    Kjeldsen, Lars
    Dignum, Helen
    Thomas, Ian F.
    Clark, Richard E.
    Milligan, Don
    Burnett, Alan K.
    BLOOD, 2015, 125 (19) : 2923 - 2932
  • [7] Venetoclax with low-dose cytarabine, a forgotten combination in patients with acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review
    Amador-Medina, Lauro Fabian
    Crespo-Solis, Erick
    Turrubiates-Herna, Francisco Javier
    Santibanez-Bedolla, Karla Edith
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2024, 46 : S322 - S331
  • [8] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Qin, Yao
    Kuang, Pu
    Liu, Ting
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 219 - 227
  • [9] Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis
    Yao Qin
    Pu Kuang
    Ting Liu
    Clinical and Experimental Medicine, 2023, 23 : 219 - 227
  • [10] Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
    Dennis, Mike
    Thomas, Ian F.
    Ariti, Cono
    Upton, Laura
    Burnett, Alan K.
    Gilkes, Amanda
    Radia, Rohini
    Hemmaway, Claire
    Mehta, Priyanka
    Knapper, Steven
    Clark, Richard E.
    Copland, Mhairi
    Russell, Nigel
    Hills, Robert K.
    BLOOD ADVANCES, 2021, 5 (24) : 5621 - 5625
12345